Grcevich 2001.

Methods	This retrospective review of medical charts compares the efficacy, safety, dosing frequency, and medication switch rates of Adderall with methylphenidate in children and adolescents with ADHD treated in a private, outpatient psychiatric clinic over 1992 to 1998. Of the evaluable patients, 54 received Adderall, and 75 received methylphenidate
Participants	Number of participants screened: not stated Number of participants included: not stated Number of participants followed up: 75 Diagnosis of ADHD: DSM‐IIIR or DSM‐IV (without hyperactivity: 12, with hyperactivity: 62) Age: mean 10.2 years old IQ: not stated Sex: 58 males, 16 females Methylphenidate‐naïve: not stated Ethnicity: not stated Country: USA Comorbidity: disruptive behaviour: 9, depressive disorder: 7, anxiety disorder: 1, communication disorder: 4, impulse control disorder: 1, Asperger's: 1, other disorders: 7 Comedication: no additional ADHD medications Sociodemographics: not stated Inclusion criteria Children and adolescents with ADHD receiving Adderall or methylphenidate and were treated in a private, outpatient psychiatric clinic between 1992 and 1998 Exclusion criteria Patients presenting for initial evaluation only or receiving ADHD medications other than methylphenidate or Adderall
Interventions	Methylphenidate type: not stated Mean methylphenidate dosage: 27 mg/day Administration schedule: not stated Duration of treatment: not stated Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Different types of non‐serious adverse events
Notes	Sample calculation: not stated Ethics approval: not stated Funding/vested interests: funded by Shire Redwood Inc. Key conclusions of the study authors: Adderall and methylphenidate provided comparable efficacy and safety in children and adolescents with ADHD Comments from the study authors: the population examined may be poorer responders to ADHD treatment than the general population. Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: not stated Supplemental information regarding IQ received October 2013 (Grcevich 2013 [pers comm])